Paser

Bruker Launches New nanoElute® 2 nano-LC For 4D-Proteomics, Advances Fluxomics Applications with MetaboScape® 2023 Software

Retrieved on: 
Monday, August 29, 2022
Software, Research, General Health, Pharmaceutical, Hardware, Medical Devices, Technology, Health Technology, Science, Biotechnology, Neurology, Health, Machine learning, Molecular biology, Metabolomics, University, Paser, Lipid, Research, Proteomics, University of Southern Denmark, Life, Protein, Associate, Disease, Solution, MOMA, Pathology, Department, JHSPH Department of Biochemistry and Molecular Biology, Bruker, Mass spectrometry, PPI, Workflow, Biochemistry, Cell, Multimedia, Capillary, Microscopy, Plasma, Karolinska Institute, Nasdaq, IMSC, MALDI, University of Ottawa, CCS, Conference, Cell biology, Risk, Â, International Mass Spectrometry Foundation, Acquisition, ISCB Senior Scientist Award, Mobile phone, Fine chemical, Medical imaging, Cancer

The nanoElute 2 features a further improved nano-LC pump design, and an intuitive and flexible user interface covering a broad range of applications from single-cell proteomics to plasma proteomics.

Key Points: 
  • The nanoElute 2 features a further improved nano-LC pump design, and an intuitive and flexible user interface covering a broad range of applications from single-cell proteomics to plasma proteomics.
  • The nanoElute 2 now also supports the label-free ProteoCHIP for the CellenONE platform for high-sensitivity single cell proteomics.
  • The nanoElute 2 dissolves the tryptic peptides directly in the plate prior to injection, avoiding manual intervention and thus streamlining our workflows.
  • Bruker is enabling scientists to make breakthrough discoveries and develop new applications that improve the quality of human life.

Bruker Launches timsTOF HT with Greater Dynamic Range for Further Enhancing Unbiased, High-Confidence 4D Proteomics™

Retrieved on: 
Monday, June 6, 2022
Technology, Research, Software, Biotechnology, Hardware, Health, Pharmaceutical, Other Science, Science, Biomarker, ASMS, HT, NL, Plasma, Proteomics, CRISPR, Blood, Therapy, Multimedia, Metabolomics, MS2, CCS, Lists of diseases, Sutro Biopharma, TOF, Unresolved complex mixture, Scripps, SCP, Gene editing, FDR, CEO, Partnership, Center, Solution, Bruker, Nanoparticle, Radbod, Liquid biopsy, University of Jena, RNA, 4D, Algorithm, Pancreatic cancer, University, TIMS, Acquisition, XR, RNA interference, Glycosylation, Cell biology, CVS, PTM, Life, Radboud University Medical Center, Research, LLC, Pro 2, Founder, Nasdaq, LC-MS, MD–PhD, Microscopy, SPD, LFQ, Drug discovery, Paser, Protein, 3D printing, Fine chemical, Medical imaging, Pharmaceutical industry, Medical device, Sapient

At the 70th ASMS meeting, Bruker Corporation (Nasdaq: BRKR) today announced the further evolution of the revolutionary 4D Multiomics timsTOF platform with the launch of the new timsTOF HT system.

Key Points: 
  • At the 70th ASMS meeting, Bruker Corporation (Nasdaq: BRKR) today announced the further evolution of the revolutionary 4D Multiomics timsTOF platform with the launch of the new timsTOF HT system.
  • The timsTOF HT includes a novel 4th-generation TIMS (trapped ion mobility separation) XR cell and 14bit digitizer for even greater dynamic range, enhanced peptide coverage and more accurate quantitation, particularly in unbiased 4D plasma and tissue proteomics and epiproteomics.
  • The timsTOF HT also is optimized for high-throughput, deep and unbiased plasma proteomics and liquid biopsy biomarker research.
  • The dia-PASEF acquisition mode on the timsTOF HT instrument quantifies proteins across a large dynamic range even in notoriously difficult samples, such as cardiac tissue, without sacrificing throughput or sensitivity.

Bruker Releases CCS-Enabled TIMScore™ and TIMS DIA-NN 4D Proteomics Software

Retrieved on: 
Monday, February 28, 2022
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Proteomics, Algorithm, Data, Peptide, Pro 2, Microscopy, Biochemistry, TIMS, Flex, Library, Paser, Phosphopeptide, SMS, IP2, PTM, Cell biology, GPU, US, Acquisition, Protein, Multimedia, Machine learning, Ambiguity, 3D, Spectrometry, Proteome, Life, Nasdaq, CCS, FLR, Phosphorylation, Research, Solution, Fine chemical, Bruker

At US HUPO, Bruker Corporation (Nasdaq: BRKR) announced its TIMS DIA-NN software for the high-throughput, deep and unbiased 4D proteomics workflow.

Key Points: 
  • At US HUPO, Bruker Corporation (Nasdaq: BRKR) announced its TIMS DIA-NN software for the high-throughput, deep and unbiased 4D proteomics workflow.
  • It now features the novel TIMScore algorithm which takes advantage of machine learning (ML) to predict CCS values of tryptic and phosphorylated peptides.
  • These features are now available in the GPU-based PaSER 2022 software release, building on the IP2 software assets acquired in 2021.
  • PaSER 2022 includes the TIMScore algorithm and TIMS DIA-NN for processing dia-PASEF workflows from timsTOF Pro 2, timsTOF SCP, and timsTOF fleX systems.

Bruker Announces Major Advances in CCS-Enabled 4D Proteomics at ASMS

Retrieved on: 
Tuesday, November 2, 2021
Other Health, Software, Research, Radiology, Medical Devices, Technology, Genetics, Science, Biotechnology, Other Technology, Other Science, Health, Online, Peptide, Dana–Farber Cancer Institute, MALDI, DDA, Life, ASMS, Multimedia, Biochemistry, Paser, Acquisition, MCP, Bruker, RNA transfection, Biology, Research, University, Machine learning, RNA, PRM, EDT, Scripps, Nature Methods, Cell biology, Solution, IRT, SCP, CCS, Microscopy, Compass, DRS, Protein, LLC, Laboratory, Nasdaq, Proteome, MALDI imaging, Method, Berlin, BioRxiv, Proteomics, FDR, Nucleotide, Dana, Ambiguity, Algorithm, Utrecht University, Time, Conference, Phosphorylation, Maxis, Automation, 3D printing, Fine chemical, Medical imaging

At the 69th ASMS meeting in Philadelphia, Bruker Corporation (Nasdaq: BRKR) announced novel CCS-enabled 4D proteomics for major capability enhancements for timsTOF Pro 2, timsTOF fleX and timsTOF SCP mass spectrometers.

Key Points: 
  • At the 69th ASMS meeting in Philadelphia, Bruker Corporation (Nasdaq: BRKR) announced novel CCS-enabled 4D proteomics for major capability enhancements for timsTOF Pro 2, timsTOF fleX and timsTOF SCP mass spectrometers.
  • Vadim Demichev and Markus Ralser at the Charit Universittsmedizin Berlin, Bruker is now integrating CCS-enabled DIA-NN into PaSER GPU-powered proteomics software for the timsTOF platform for enhanced identification and quantification.
  • Were also pleased to see Bruker incorporating the open-source version of Vadim Demichevs DIA-NN in its PaSER real-time proteomics workflows and look forward to working with Bruker to further improve 4D-Proteomics workflows.
  • Dr. Marto will present at the Bruker Press Conference at ASMS on November 2nd at 11 am EDT.